YZYijian Zhu

Yijian Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yijian Zhu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Safety and Feasibility of Compound Glycyrrhizin–Based Combination Therapy for Coexisting Facial Vitiligo and Melasma: A Real-World Retrospective Study

    by Zhengzhou Shi, Yijian Zhu, Qianqian Wang, Li Zhang, Suqing Liu, Min Jiang, Leihong Xiang

    Background: The coexistence of vitiligo and melasma poses a therapeutic challenge, as interventions for one condition may adversely affect the other. Compound glycyrrhizin (CG), an immunomodulatory agent widely used in vitiligo management in China, has been explored in combination treatment strategies. However, data on its use in patients concurrently affected by melasma are limited. Methods: This retrospective analysis included 29 adults with facial non-segmental vitiligo and coexisting melasma who received oral CG for 12 months, in combination with topical tacrolimus and phototherapy using melasma shielding. Clinical parameters were evaluated using the Facial Vitiligo Area Scoring Index (F-VASI) and Melasma Area and Severity Index (MASI), along with standardized facial photography and serum chemokine profiling. Results: Among the 29 patients who underwent combination therapy, the mean baseline F-VASI was 0.99 ± 0.65, which decreased by 54.93% ± 19.99% over 12 months. Initial repigmentation was observed at a mean of 4.17 ± 1.26 months. Melasma severity remained largely stable throughout the treatment period (baseline MASI 16.51 ± 7.31 vs 15.97 ± 7.02 post-treatment). In parallel, serum CXCL10 and CCL20 levels showed a downward trend over time, coinciding with clinical improvement. Conclusion: In this retrospective real-world cohort, facial vitiligo improved during 12 months of CG-based combination therapy without apparent worsening of coexisting melasma. The regimen was well tolerated, with no severe adverse events. Controlled studies are needed to confirm efficacy and clarify the independent role of CG. Plain Language Summary: This retrospective real-world study evaluates the efficacy and safety of oral CG in patients with coexisting facial vitiligo and melasma. Significant repigmentation was achieved in vitiligo without worsening melasma severity, despite concurrent phototherapy. Serum CXCL10 and CCL20 levels decreased in parallel with vitiligo improvement, supporting an anti-inflammatory mechanism. CG was well tolerated, with no serious adverse events observed during 12-month follow-up. Findings support the potential of CG as a safe, integrative approach for managing complex pigmentary disorders.

  • Open Access

    Effect of platelet-rich plasma in refractory vitiligo by promoting the differentiation of dermal melanocyte progenitors via IGFBP-2/RhoA/YAP pathway

    by Yijian Zhu, Suqing Liu, Chen Wang, Zhongyi Xu, Zhengzhou Shi, Xiaoxue Xing, Yanjun Dan, Qianqian Wang, Jiaqiang Wu, Li Chen, et al.


  • Clinical and molecular markers of vitiligo: a narrative review of early-stage insights into disease activity and treatment response

    by Zhe Zhu, Yijian Zhu, Yijie Xuan, Yue Wu, Yang Liu, Xiuxiu Wang, Li Zhang, Leihong Xiang, Chengfeng Zhang

    Vitiligo fluctuates between progressive and quiescent states, complicating decisions about when to intervene, how to select therapy and how to monitor response. In this review, we integrate bedside phenotypes with multilevel molecular readouts to summarize emerging evidence linking clinical signs and biologic signals to disease activity and treatment response in clinical studies. For staging, tool-free and standardized assessments such as Koebner phenomenon, confetti-like depigmentation, Wood’s lamp and dermoscopy provide visible clues associated with active disease. Measurements from blood, suction blister fluid and tissue offer complementary insights into local and systemic immune activation, suggesting how molecular signals may relate to progression. For stratification, factors such as age, lesion site, disease stability, comorbidities and dermoscopic border features have been tentatively associated with differential responses to therapies such as phototherapy or transplantation. Similarly, lower baseline levels of inflammatory, chemotactic and cytotoxic markers have been informally aligned with better outcomes in clinical studies. For monitoring, the response phase typically mirrors a reversal of progression: waning inflammatory signalling, reduced effector-cell burden and partial recovery of melanogenic programmes provide molecular parallels to clinical improvement. Across these domains, the interferon-γ–CXCL9/CXCL10–CD8+ T-cell axis emerges as the most recurrent immune signature, demonstrating reproducible associations with activity, prognosis and treatment response. Future work should prioritize harmonized definitions of disease activity, standardized sampling standards and multicentre validation of integrated biomarker panels. It is equally critical to determine whether proposed biomarker thresholds relate to clinically meaningful endpoints, thereby translating early-stage discoveries into reliable frameworks for staging, stratification and monitoring.


  • Heat shock protein 70/toll-like receptor 2 orchestrates melanocyte ferroptosis in the onset of vitiligo

    by Xiaoxue Xing, Jie Ren, Yijian Zhu, Yi Lin, Zhongyi Xu, Li Chen, Xiuxiu Wang, Chengfeng Zhang, Leihong Xiang


  • Comparative Study of a 1064 nm Fractional Picosecond Laser Versus Intense Pulsed Light in Facial Rejuvenation: A Prospective Randomized Trial

    by Jingtao Zhang, Changyue Wu, Ye Liu, Fang Yan, Qinyi Chen, Yijian Zhu, Leihong Flora Xiang, Jie Ren

    Background and Objectives: Skin aging, characterized by wrinkles, pigment disorders, and enlarged pores, is driven primarily by photoaging. While a 1064 nm fractional picosecond laser shows efficacy in skin rejuvenation, comparative studies with intense pulsed light (IPL) remain limited. This randomized controlled trial (RCT) aimed to compare the efficacy and safety of the 1064 nm fractional picosecond laser with IPL in Asian women. Methods: In this single‐center RCT, 38 Asian women (30–60 years) were randomized to receive 1064 nm Nd:YAG picosecond laser with a fractional optic (1064 nm Ps) ( n = 19) or IPL ( n = 19) therapy for three treatments. Baseline and post treatments Global Score for Photoaging (GSP), fine lines and pigmented spots scores were assessed by two blinded dermatologists based on VISIA photographs. Skin texture, T‐zone pores and skin tone were measured with VISIA, C‐Cube and Delfin Skin Color Catch. Transepidermal water loss (TEWL) was measured before and after a single treatment by Delfin Vapometer. All adverse events were documented. Results: 1064 nm Ps outperformed IPL in the periorbital fine lines ( p = 0.0315) and T‐zone pore counts ( p = 0.0473). GSP, infraorbital texture area, pigmented spots and lightness ( L *), compared to baseline, significantly improved after treatments in each group, while there was no difference between two groups. Regarding safety, erythema was the most frequent transient response in both groups. Conclusions: Both 1064 nm fractional picosecond laser and IPL were effective and safe in treatments of facial rejuvenation. Compared to IPL, 1064 nm fractional picosecond laser excelled in periorbital fine lines and T‐zone pores. Clinical Trial Registration: This trial was registered at ClinicalTrials.gov (identifier: NCT07122310).


  • Effectiveness and Safety of Oral Compound Glycyrrhizin Followed by Phototherapy for the Treatment of Progressive Vitiligo in Children

    by Li Zhang, Jian Zhang, Suqing Liu, Zhengzhou Shi, Yijian Zhu, Min Jiang, Leihong Xiang

    Childhood vitiligo, distinct from its adult counterpart, presents unique treatment challenges. Glycyrrhizin inhibits the release of high‐mobility group box 1 (HMGB1) protein from keratinocytes, preventing melanocyte apoptosis and autophagy. Furthermore, the orally administered compound glycyrrhizin (OCG) effectively treats various autoimmune disorders, demonstrating long‐term efficacy, safety, and tolerability. This study compared the efficacy of OCG and oral prednisone (OP), followed by phototherapy, in patients with progressive childhood vitiligo at 52 weeks' follow‐up. Fifty children with vitiligo were randomized into two groups according to treatment: OCG (50–150 mg/day) followed by phototherapy (n = 25) and OP (5–10 mg/day) followed by phototherapy (n = 25). At Week 24, a halt in disease progression (HDP) was observed in 20 (80%) patients in the OCG group and 21 (84%) in the OP group, with no significant difference (p > 0.99). However, the mean time to achieve HDP was significantly shorter in the OP group than in the OCG group (14.73 ± 4.84 vs. 19.13 ± 4.82 weeks; p < 0.01). In addition, serum HMGB1 concentrations were significantly reduced after treatment with OCG at Week 24 (3.02 ± 0.83 vs. 0.95 ± 0.36 ng/mL [p < 0.01]; OP, 2.79 ± 0.16 vs. 1.03 ± 0.34 ng/mL [p < 0.01]). The decline in Vitiligo Area Scoring Index (VASI) score at the end of follow‐up (i.e., Week 52) did not show a statistically significant difference between the OCG and OP groups (52.31% ± 14.86% vs. 55.71% ± 21.23%; p = 0.55). The therapeutic response of the clinical markers of progression was good and comparable between the OCG and OP groups. OCG demonstrated similar efficacy to OP followed by phototherapy in controlling disease activity and promoting repigmentation in children with vitiligo at 52 weeks of follow‐up. Trial Registration: ChiCTR2400086844


  • Photobiomodulation Using 830 nm Lighting‐Emitting Diode Inhibits Melanogenesis via FOXO3a in Human Melanocyte

    by Yanjun Dan, Li Chen, Shanglin Jin, Xiaoxue Xing, Yijian Zhu, Min Jiang, Chengfeng Zhang, Leihong Flora Xiang

    Photobiomodulation (PBM) using 830 nm light‐emitting diode (LED) benefits tissue regeneration, wound healing and neural stimulation. However, there is not much exploration of its effect on melanocytes and ex vivo skin model. This study aims to investigate the mechanism behind the anti‐melanogenic activity of 830 nm LED and provides evidence for its activity in human ex vivo skin model. Our results showed that 830 nm LED at fluences ranging from 5 to 20 J/cm2 inhibited melanosome maturation and reduced melanin content, tyrosinase activity and melanogenesis‐related proteins. 830 nm LED inhibited the phosphorylation of AKT and its downstream FOXO3a, leading to nuclear translocation of FOXO3a. Furthermore, FOXO3a knockdown and AKT activator like SC79 could reverse the melanogenesis inhibition phenotype induced by 830 nm LED. In human ex vivo skin model, Fontana–Masson staining revealed a decrease in epidermal basal pigmentation after 830 nm LED irradiation. Taken together, 830 nm LED demonstrated the anti‐melanogenic activity via FOXO3a.